Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD's interaction with conventional anticancer drugs; (d) CBD's potential in palliative care for cancer patients; (e) CBD's tolerability and reported side effects; (f) CBD delivery for anticancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951434 | PMC |
| http://dx.doi.org/10.3390/ph15030366 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Daily Use of a Broad-Spectrum Cannabidiol Supplement Produces Detectable Concentrations of Cannabinoids in Urine Prohibited by the World Anti-Doping Agency: An Effect Amplified by Exercise.
Med Sci Sports Exerc
September 2025
Research Institute of Sport and Exercise Sciences (RISES), Liverpool John Moores University, Byrom Street, Liverpool, UNITED KINGDOM.
Background: Cannabidiol (CBD), a non-intoxicating phytocannabinoid, is used by athletes to enhance recovery and manage other conditions (e.g., poor sleep, anxiety).
View Article and Find Full Text PDFOromucosal as an Alternative Method for Administration of Cannabis Products in Rodents.
J Vis Exp
August 2025
Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro;
Oral administration of drugs in laboratory rodents such as rats is conventionally performed using the gavage technique. Despite effectiveness, gavage can induce distress associated with restraint, especially following repeated animal handling. To mitigate these adverse effects and reduce morbidity associated with traditional methods, we explored oromucosal/buccal administration of cannabidiol (CBD)-enriched Cannabis extract.
View Article and Find Full Text PDFAnalysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy.
Front Pharmacol
August 2025
Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, "Dr. Bernardo Sepúlveda", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Background: Cannabidiol (CBD) reduces the frequency of seizures in individuals with specific epileptic syndromes, but its effectiveness for other types of drug-resistant epilepsy (DRE) is unclear. CYP450 enzymes primarily metabolize CBD. The aim of this study was to identify CYP450 genotypes regarding the response of CBD treatment concomitant with anti-seizure drugs in patients with DRE.
View Article and Find Full Text PDFAnalgesic and toxicological evaluation of cannabidiol-rich Moroccan L. (Khardala variety) extract: Evidence from an and study.
Open Life Sci
September 2025
Physiology and Physiopathology Team, Faculty of Sciences, Genomic of Human Pathologies Research Centre, Mohammed V University in Rabat, Rabat, Morocco.
The legalization of cannabis for industrial and medicinal purposes has significantly expanded worldwide. This study delves into the analgesic potential toxicity study of chloroformic extract from the Moroccan L. () cultivar, Khardala (KH extract).
View Article and Find Full Text PDFEffects of Cannabinoids on Emotional States and Alcohol Use Among Underrepresented Groups: Moderation by Perceived Discrimination.
Hum Psychopharmacol
September 2025
Psychology and Neuroscience, University of Colorado Boulder, Boulder, Colorado, USA.
Objective: This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research.
Methods: Participants were either not using cannabis, using cannabis with THC, or using cannabis with CBD and were assessed at baseline, 2 weeks, and 4-weeks following ad libitum use of a legal market cannabis product that was randomly assigned to them. Primary outcomes included scores on the Depression Anxiety Stress (DASS) Scale and number of drinking days.